Quick Answer
Transcode Therapeutics, Inc. reported Operating Income of -$15.66 million for fiscal year 2024.
Transcode Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$15.66M | +19.4% |
| 2023 | -$19.42M | -4.2% |
| 2022 | -$18.63M | -202.9% |
| 2021 | -$6.15M | -746.6% |
| 2020 | -$726.6K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.56M | -110.6% | -8.1% |
| June 30, 2025 | -$4.22M | +17.5% | -33.1% |
| March 31, 2025 | -$3.17M | +3.6% | -46.4% |
| September 30, 2024 | -$2.17M | +59.2% | +57.7% |
| June 30, 2024 | -$5.11M | +0.2% | -55.5% |
| March 31, 2024 | -$3.29M | +32.7% | +38.1% |
| September 30, 2023 | -$5.31M | -7.2% | -3.7% |
| June 30, 2023 | -$5.12M | -8.8% | -4.8% |
- Transcode Therapeutics, Inc. showed an increase of +19.4% in Operating Income compared to the prior fiscal year.
- Over the 2020–2024 period, Transcode Therapeutics, Inc.’s operating income has declined by 2055.3% (from -$726.6 thousand to -$15.66 million).
- The most recent figure is from Transcode Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: